{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Uterine+Corpus+Neoplasm",
    "query": {
      "condition": "Malignant Uterine Corpus Neoplasm"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 32,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Uterine+Corpus+Neoplasm&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T16:00:50.963Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04634617",
      "title": "Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Endometrial Carcinoma",
        "Malignant Uterine Neoplasm",
        "Uterine Corpus Cancer",
        "Uterine Corpus Sarcoma"
      ],
      "interventions": [
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 310,
      "start_date": "2020-01-09",
      "completion_date": "2027-04-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-09-27T16:00:50.963Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04634617"
    },
    {
      "nct_id": "NCT03508570",
      "title": "Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Peritoneal Neoplasm",
        "Malignant Retroperitoneal Neoplasm",
        "Metastatic Cervical Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Fallopian Tube Carcinoma",
        "Metastatic Malignant Female Reproductive System Neoplasm",
        "Metastatic Ovarian Carcinoma",
        "Metastatic Primary Peritoneal Carcinoma",
        "Peritoneal Carcinomatosis",
        "Platinum-Refractory Fallopian Tube Carcinoma",
        "Platinum-Refractory Malignant Female Reproductive System Neoplasm",
        "Platinum-Refractory Ovarian Carcinoma",
        "Platinum-Refractory Primary Peritoneal Carcinoma",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Malignant Female Reproductive System Neoplasm",
        "Platinum-Resistant Ovarian Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Recurrent Cervical Carcinoma",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Malignant Female Reproductive System Neoplasm",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Stage IV Fallopian Tube Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Primary Peritoneal Cancer AJCC v8",
        "Stage IVA Fallopian Tube Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Primary Peritoneal Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Fallopian Tube Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Primary Peritoneal Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacokinetic Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2018-09-21",
      "completion_date": "2024-11-11",
      "has_results": false,
      "last_update_posted_date": "2025-05-22",
      "last_synced_at": "2026-09-27T16:00:50.963Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03508570"
    },
    {
      "nct_id": "NCT05256225",
      "title": "Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Carcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Dedifferentiated Carcinoma",
        "Endometrial Endometrioid Adenocarcinoma",
        "Endometrial Mixed Cell Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Endometrial Undifferentiated Carcinoma",
        "Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "High-Dose-Rate Vaginal Cuff Brachytherapy",
          "type": "RADIATION"
        },
        {
          "name": "Hyaluronidase-zzxf/Pertuzumab/Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        },
        {
          "name": "Trastuzumab/Hyaluronidase-oysk",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 360,
      "start_date": "2022-11-16",
      "completion_date": "2027-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-09-27T16:00:50.963Z",
      "location_count": 409,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 307 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05256225"
    },
    {
      "nct_id": "NCT01225887",
      "title": "Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Adenocarcinoma",
        "Endometrial Clear Cell Adenocarcinoma",
        "Endometrial Mucinous Adenocarcinoma",
        "Endometrial Serous Adenocarcinoma",
        "Endometrial Squamous Cell Carcinoma",
        "Endometrial Transitional Cell Carcinoma",
        "Endometrial Undifferentiated Carcinoma",
        "Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm",
        "Recurrent Uterine Corpus Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 37,
      "start_date": "2011-10",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-10-09",
      "last_synced_at": "2026-09-27T16:00:50.963Z",
      "location_count": 59,
      "location_summary": "Burbank, California • Aurora, Colorado • Hartford, Connecticut + 40 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01225887"
    },
    {
      "nct_id": "NCT03968406",
      "title": "Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Female Reproductive System Neoplasm",
        "Recurrent Cervical Carcinoma",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Vaginal Carcinoma",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Fallopian Tube Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Primary Peritoneal Cancer AJCC v8",
        "Stage IV Uterine Corpus Cancer AJCC v8",
        "Stage IV Vaginal Cancer AJCC v8",
        "Stage IVA Cervical Cancer AJCC v8",
        "Stage IVA Fallopian Tube Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Primary Peritoneal Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVA Vaginal Cancer AJCC v8",
        "Stage IVB Cervical Cancer AJCC v8",
        "Stage IVB Fallopian Tube Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Primary Peritoneal Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8",
        "Stage IVB Vaginal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-09-26",
      "completion_date": "2027-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-09-27T16:00:50.963Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Houston, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03968406"
    },
    {
      "nct_id": "NCT06349642",
      "title": "Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Early Stage Triple-Negative Breast Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Cervical Carcinoma",
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Esophageal Carcinoma",
        "Metastatic Liver Carcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Skin Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Resectable Lung Non-Small Cell Carcinoma",
        "Early Stage Lung Non-Small Cell Carcinoma",
        "Resectable Malignant Solid Neoplasm",
        "Resectable Triple-Negative Breast Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Recurrent Cervical Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Esophageal Carcinoma",
        "Recurrent Liver Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Recurrent Malignant Skin Neoplasm",
        "Recurrent Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Tissue Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2024-04-24",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-09-27T16:00:50.963Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06349642"
    },
    {
      "nct_id": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Bladder Carcinoma",
        "Breast Carcinoma",
        "Cervical Carcinoma",
        "Colon Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma",
        "Esophageal Carcinoma",
        "Exocrine Pancreas Carcinoma",
        "Gastric Carcinoma",
        "Glioma",
        "Head and Neck Carcinoma",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Kidney Carcinoma",
        "Liver Carcinoma",
        "Lung Carcinoma",
        "Lymphoma",
        "Malignant Uterine Corpus Neoplasm",
        "Malignant Uterine Neoplasm",
        "Melanoma",
        "Multiple Myeloma",
        "Ovarian Carcinoma",
        "Prostate Carcinoma",
        "Rectal Carcinoma",
        "Recurrent Bladder Carcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Cervical Carcinoma",
        "Recurrent Colon Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Recurrent Esophageal Carcinoma",
        "Recurrent Gastric Carcinoma",
        "Recurrent Glioma",
        "Recurrent Head and Neck Carcinoma",
        "Recurrent Liver Carcinoma",
        "Recurrent Lung Carcinoma",
        "Recurrent Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Malignant Uterine Corpus Neoplasm",
        "Recurrent Melanoma",
        "Recurrent Multiple Myeloma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Recurrent Rectal Carcinoma",
        "Recurrent Skin Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma",
        "Skin Carcinoma",
        "Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Adavosertib",
          "type": "DRUG"
        },
        {
          "name": "Afatinib",
          "type": "DRUG"
        },
        {
          "name": "Afatinib Dimaleate",
          "type": "DRUG"
        },
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Copanlisib",
          "type": "DRUG"
        },
        {
          "name": "Copanlisib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Cytology Specimen Collection Procedure",
          "type": "OTHER"
        },
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Defactinib",
          "type": "DRUG"
        },
        {
          "name": "Defactinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Erdafitinib",
          "type": "DRUG"
        },
        {
          "name": "Fexagratinib",
          "type": "DRUG"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Larotrectinib",
          "type": "DRUG"
        },
        {
          "name": "Larotrectinib Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PI3K-beta Inhibitor GSK2636771",
          "type": "DRUG"
        },
        {
          "name": "Radiologic Examination",
          "type": "PROCEDURE"
        },
        {
          "name": "Radionuclide Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Relatlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        },
        {
          "name": "Taselisib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ulixertinib",
          "type": "DRUG"
        },
        {
          "name": "Vismodegib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6452,
      "start_date": "2015-08-17",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-27T16:00:50.963Z",
      "location_count": 1405,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02465060"
    },
    {
      "nct_id": "NCT05786456",
      "title": "e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malignant Female Reproductive System Neoplasm",
        "Stage III Cervical Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Uterine Corpus Cancer AJCC v8",
        "Stage III Vaginal Cancer AJCC v8",
        "Stage III Vulvar Cancer AJCC v8",
        "Stage IV Cervical Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Uterine Corpus Cancer AJCC v8",
        "Stage IV Vaginal Cancer AJCC v8",
        "Stage IV Vulvar Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Discussion",
          "type": "PROCEDURE"
        },
        {
          "name": "Informational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Media Intervention",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Telephone-Based Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 23,
      "start_date": "2024-07-19",
      "completion_date": "2026-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-09-27T16:00:50.963Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05786456"
    },
    {
      "nct_id": "NCT07671937",
      "title": "INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Corpus Uteri Cancer",
        "Ovary Cancer",
        "Pancreas Cancer",
        "Other Female Genital Malignant Neoplasms"
      ],
      "interventions": [
        {
          "name": "INSPIRE (INtegrating Systematic PatIent-Reported Evaluations)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Capture of patient-reported outcomes",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Enhanced Clinician Awareness",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2748,
      "start_date": "2026-09-01",
      "completion_date": "2031-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-09-27T16:00:50.963Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07671937"
    },
    {
      "nct_id": "NCT05039801",
      "title": "IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Endometrial Carcinoma",
        "Advanced Head and Neck Squamous Cell Carcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Advanced Melanoma",
        "Advanced Ovarian Clear Cell Adenocarcinoma",
        "Chondrosarcoma",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Pathologic Stage III Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Recurrent Ovarian High Grade Serous Adenocarcinoma",
        "Refractory Endometrial Carcinoma",
        "Refractory Head and Neck Squamous Cell Carcinoma",
        "Refractory Melanoma",
        "Refractory Ovarian Clear Cell Adenocarcinoma",
        "Refractory Ovarian High Grade Serous Adenocarcinoma",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage III Uterine Corpus Cancer AJCC v8",
        "Stage IIIA Ovarian Cancer AJCC v8",
        "Stage IIIA Uterine Corpus Cancer AJCC v8",
        "Stage IIIA1 Ovarian Cancer AJCC v8",
        "Stage IIIA2 Ovarian Cancer AJCC v8",
        "Stage IIIB Ovarian Cancer AJCC v8",
        "Stage IIIB Uterine Corpus Cancer AJCC v8",
        "Stage IIIC Ovarian Cancer AJCC v8",
        "Stage IIIC Uterine Corpus Cancer AJCC v8",
        "Stage IIIC1 Uterine Corpus Cancer AJCC v8",
        "Stage IIIC2 Uterine Corpus Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IV Uterine Corpus Cancer AJCC v8",
        "Stage IVA Ovarian Cancer AJCC v8",
        "Stage IVA Uterine Corpus Cancer AJCC v8",
        "Stage IVB Ovarian Cancer AJCC v8",
        "Stage IVB Uterine Corpus Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Glutaminase-1 Inhibitor IACS-6274",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2021-09-30",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-09-27T16:00:50.963Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05039801"
    }
  ]
}